Stockholm3 Prostate Cancer Risk Assessment
Advanced prostate cancer risk assessment using the Stockholm3 algorithm, available at our City of London clinic.
Stockholm3 Prostate Cancer Risk Assessment
All-inclusive price
- Blood draw by registered nurse
- Comprehensive lab analysis
- Detailed results report
- Detailed nurse-written review
- Follow-up recommendations
Or call 020 7183 3709
Pay at the clinic on the day of your appointment
About This Screening
Stockholm3 Prostate Cancer Risk Assessment
Prostate cancer is the most commonly diagnosed cancer in men in the UK, with approximately 52,000 new cases annually. Traditional PSA-based screening, while widely available, has well-documented limitations — it can miss clinically significant cancers in some men while triggering unnecessary biopsies in others due to false-positive results. The Stockholm3 test was developed to address these limitations.
The Stockholm3 test combines PSA measurement with additional protein biomarkers including free PSA, intact PSA, hK2, MSMB, and MIC1, integrated through a clinically validated algorithm. This algorithm also incorporates clinical variables including age and family history of prostate cancer. The resulting Stockholm3 score provides a personalised risk assessment for clinically significant prostate cancer (Gleason Grade Group ≥ 2), which is the type of prostate cancer most likely to require treatment.
Key Highlights
- Improved accuracy compared to PSA alone
- Reduces unnecessary biopsies by up to 50%
- Enhanced detection of clinically significant cancer
- Validated in clinical trials with over 75,000 participants
- Algorithm-based personalised risk assessment
The test has been validated in large prospective clinical studies involving over 75,000 men across multiple countries. In validation studies, the Stockholm3 test detected the same number of clinically significant prostate cancers as standard PSA testing while reducing the number of unnecessary biopsies by approximately 50%. This is clinically important because prostate biopsies carry risks including infection, bleeding, and anxiety.
The Stockholm3 test is particularly appropriate for men aged 50 and above, or from age 45 for men with a family history of prostate cancer or men of African-Caribbean descent, who have a statistically higher incidence of the disease. It is also suitable for men with a mildly elevated PSA (typically 1.5–10 ng/mL) where additional risk stratification is needed before deciding whether biopsy is appropriate.
It is important to understand that this test provides a risk assessment — it is not a definitive diagnostic test for prostate cancer. A positive result indicates elevated risk that may warrant further investigation, typically with MRI and potentially targeted biopsy. A low-risk result does not exclude the possibility of prostate cancer entirely.
The blood sample is collected at our City of London clinic and processed by a UKAS-accredited laboratory.
What's Included
Comprehensive testing covering all essential biomarkers for a complete health picture.
Prostate Cancer Risk Assessment
- Prostate Specific Antigen (PSA)
- Stockholm3 Prostate Cancer Risk Algorithm
- Reflex testing included where PSA > 1.5
Enhanced Prostate Cancer Risk Stratification
The Stockholm3 test represents a significant advancement over traditional PSA testing. Developed in Sweden and validated in clinical trials involving over 75,000 men, it combines multiple biomarkers with a sophisticated algorithm to provide more accurate prostate cancer risk assessment, reducing unnecessary biopsies by up to 50%.
Improved accuracy compared to PSA alone
Reduces unnecessary biopsies by up to 50%
Enhanced detection of clinically significant cancer
Validated in clinical trials with over 75,000 participants
Algorithm-based personalised risk assessment
Endorsed by urological guidelines internationally
Who Should Take This Test?
Men Over 50
Prostate cancer risk increases with age. Screening is generally appropriate for men from age 50.
Family History
Men with a father or brother diagnosed with prostate cancer have 2-3 times elevated risk and may consider testing from age 45.
Elevated PSA
If PSA is elevated, Stockholm3 can assist in determining whether biopsy is clinically indicated.
African or Caribbean Heritage
Men of African or Caribbean descent have epidemiologically higher prostate cancer rates and may benefit from earlier screening.
How to Prepare
Follow these steps before your appointment for the most accurate results.
No fasting is required for this blood test.
Avoid ejaculation for 48 hours before testing, as this can temporarily elevate PSA levels.
Avoid vigorous cycling or activities that apply pressure to the perineal area for 48 hours before testing.
Continue taking prescribed medications as normal — inform our team if you take 5-alpha reductase inhibitors (e.g. finasteride) as these affect PSA levels.
Inform our team of any family history of prostate cancer, as this is incorporated into the Stockholm3 algorithm.
Ready to Take Control of Your Health?
Book your Stockholm3 Prostate Cancer Risk Assessment today and get comprehensive insights into your health. Results available in 2 weeks.
Frequently Asked Questions
Explore More Screenings
You Might Also Be Interested In
Patient Reviews
We're preparing to welcome our first patients at St Paul's Medical & Dental. Patient reviews will be available once we open our doors in April 2026.
We look forward to providing exceptional dental and medical care to the City of London community.
Meet Our Medical Team
Our experienced medical team is fully qualified and registered with the GMC and NMC, delivering safe, high-quality care in line with the highest professional standards.
Because our patients deserve nothing less.
Registered. Regulated. Trusted.
At St Paul's Medical & Dental, we are in process of registering with the Care Quality Commission (CQC) and our clinicians are registered with the relevant UK regulatory bodies, including the GDC and GMC. Our dentists, dental nurses and medical professionals deliver care that meets the highest clinical, safety and ethical standards, because our patients deserve nothing less.
